COMMUNIQUÉS West-GlobeNewswire

Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
26/02/2019
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain on-track Company to [...]
Zomedica Pharmaceuticals Corp. Announces Year End 2018 Financial Results
26/02/2019
ANN ARBOR, Mich., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported [...]
VIVUS Reports Fourth Quarter 2018 Financial Results
26/02/2019
Company to host conference call today at 4:30pm ET CAMPBELL, Calif., Feb. 26, 2019 (GLOBE NEWSWIRE) -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a specialty pharmaceutical company committed to the development and [...]
Wright Medical Group N.V. Reports 2018 Fourth Quarter and Full-Year Financial Results and Provides 2019 Annual Guidance
26/02/2019
Fourth Quarter 2018 Net Sales, Including Cartiva, of $238 Million; Full-Year 2018 Net Sales, Including Cartiva, of $836 Million Cartiva Revenue of $9.5 Million From October 10, 2018 Closing Date Through Year-End Fourth [...]
Voyager Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
26/02/2019
Initiated RESTORE-1 Phase 2 trial for VY-AADC for Parkinson’s disease Began IND-enabling preclinical studies for ALS-SOD1 and Huntington’s disease programs Recently announced strategic collaborations with funding for [...]
WW Announces Fourth Quarter and Full Year 2018 Results
26/02/2019
Provides Full Year 2019 Guidance End of Period Subscribers up 22% year-over-year to 3.9 million Total Paid Weeks in Q4 2018 up 23% year-over-year; Total Paid Weeks in FY 2018 up 26% year-over-year Revenues in Q4 2018 of [...]
Dynavax Announces Fourth Quarter and Full Year 2018 Financial Results
26/02/2019
Fourth quarter 2018 HEPLISAV-B ® net product revenue of $3.9 million Phase Ib/2 safety data for inhaled DV281 will be presented at the AACR Annual Meeting SD-101 demonstrates consistent and meaningful clinical benefit [...]
Codexis Reports 2018 Fourth Quarter and Full Year Financial Results
26/02/2019
2018 revenues of $61 million include a 50% increase in R&D revenue Introduces 2019 financial guidance Conference call begins at 4:30 pm Eastern time today Accompanying slide presentation available on Investor [...]
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018
26/02/2019
TEGSEDI™ (inotersen) commercially available in United States, European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference Call Webcast Tuesday, [...]
Eloxx Pharmaceuticals Announces Participation in the HIT-CF Project on Cystic Fibrosis
26/02/2019
Eloxx is evaluating ELX-02, its lead investigational compound, for the treatment of Cystic Fibrosis in patients with nonsense mutations WALTHAM, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., ( [...]
OpGen Reports Fourth Quarter and 2018 Financial Results and Provides Business Update
26/02/2019
Conference call begins at 4:30 p.m. Eastern time today GAITHERSBURG, Md., Feb. 26, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and 12 months ended [...]
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018
26/02/2019
– Epidiolex ® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the U.S. in November to high awareness and demand – – GW moves to a new fiscal year-end beginning [...]
Merit Medical Reports Earnings for Fourth Quarter and Year Ended December 31, 2018, Gives 2019 and 2020 Guidance
26/02/2019
Q4 2018 worldwide revenue of $233.2 million, up 22.2% as reported over Q4 2017 Q4 2018 core revenue on a comparable, constant currency basis* up 13.1% over Q4 2017 Q4 2018 GAAP EPS was $0.16, compared to $0.13 in Q4 [...]
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
26/02/2019
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN SAN DIEGO, [...]
MacroGenics Provides Update on Corporate Progress and 2018 Financial Results
26/02/2019
Margetuximab: Positive Phase 3 SOPHIA study with BLA submission planned for second half of 2019; Plans to initiate Phase 2/3 registration-directed, front-line gastric cancer study Enoblituzumab: Encouraging anti-PD-1 [...]
Dermira Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
26/02/2019
QBREXZA™ (glycopyrronium) cloth 2018 net product sales of $3.0 million Over 14,500 prescriptions for QBREXZA written in first three months of launch Secured QBREXZA coverage for approximately 76% of total U.S. [...]
Axogen, Inc. Reports 2018 Fourth Quarter and Full Year 2018 Financial Results
26/02/2019
Fourth Quarter Revenue of $23.4 million, representing 38% growth over prior year Full Year 2018 Revenue of $83.9 million, representing 39% growth over prior year ALACHUA, Fla., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Axogen, [...]
Alder BioPharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
26/02/2019
BOTHELL, Wash., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced [...]
VitalHub Corp. Announces Agreement to Acquire the Assets of the Oak Group, Inc.
26/02/2019
TORONTO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VITALHUB CORP. (TSXV: VHI) (the “Company” or “VitalHub”), is pleased to announce that today it has entered into an arm’s length agreement (the “Agreement”) to acquire [...]

Pages